Outcomes Of Stage D Heart Failure Patients On Palliative Inotrope Therapy In The Hospice Setting: A Single Center Retrospective Cohort Study

Umer A. Esbhani,Eric Bush,Anirudh Rao
DOI: https://doi.org/10.1016/j.cardfail.2023.10.303
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Continuous intravenous inotrope therapy (CIIS) is a Class 2b recommendation in the ACC/AHA heart failure (HF) guidelines and is being increasingly used to combat symptoms and increase quality of life of patients with end stage HF. Most hospice agencies in the region, except for one, do not accept patients on inotrope therapy. Therefore, our aim is to study outcomes of Stage D HF patients on CIIS under hospice care to learn if this is a viable approach to improve end of life care in this patient population. Methods This is a retrospective cohort study of patients on CIIS as palliative therapy who were admitted to Hospice of the Chesapeake between 2018-2022. Electronic health records were reviewed, and data was abstracted for statistical analysis using descriptive statistics. Results Twenty-one patients, mean age 72.9 years (SD = 8.03), 62% male and 38% female, met study criteria, out of which 48% of patients identified as Caucasian and 52% as African American. The choice of inotrope was dobutamine for 33% of patients and milrinone for 67% of patients. Code status on admission was full code for 24% of patients and DNR/DNI for 76% of patients. Out of all patients, 29% had one hospitalization during their hospice stay, 5% had three hospitalizations, and 66% had no hospitalizations. Mean length of stay was 49.6 days (SD = 102.4), or 28.1 days (SD = 29.2) when excluding one outlier. Mean visits by interdisciplinary team members was 1.16 (SD = 1.12) per day. When accounting for length of stay, mean visits per day for short hospice stay (10 or less days) were 1.94 (SD = 1.40), whereas mean visits per day for longer hospice stay (11 or more days) were 0.68 (SD = 0.52). Regarding final outcomes, 24% of patients were discharged alive, 14% died at a hospice facility, 10% at a hospital and 52% at home. Out of all patients, 76% were on low dose PRN opioids (e.g. 5mg PO morphine q3h or equivalent) and 24% were on high dose PRN opioids (e.g. 5mg IV morphine q1h or equivalent). Conclusion To our knowledge, this is the first ever study describing outcomes of Stage D HF patients on palliative CIIS under hospice care. Sample sizes are relatively small in such populations as this is a select cohort, therefore further research is needed not only to consolidate these findings but also eventually draw comparisons with the general population (i.e. Stage D HF patients not on palliative CIIS under hospice care). This may pave the way for new possibilities pertaining to hospice care models and more importantly improve end of life care.
cardiac & cardiovascular systems
What problem does this paper attempt to address?